IDNNA
Pharmaceutical compound
From Wikipedia, the free encyclopedia
IDNNA, also known as 4-iodo-2,5-dimethoxy-N,N-dimethylamphetamine or as N,N-dimethyl-DOI, is a chemical compound of the phenethylamine, amphetamine, and DOx families.[1][2][3] It is the N,N-dimethyl derivative of the psychedelic drug DOI.[1][2][3]
- None
| Clinical data | |
|---|---|
| Other names | 4-Iodo-2,5-dimethoxy-N,N-dimethylamphetamine; 2,5-Dimethoxy-4-iodo-N,N-dimethylamphetamine; N,N-Dimethyl-DOI |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H20INO2 |
| Molar mass | 349.212 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Use and effects
Chemistry
Synthesis
The chemical synthesis of IDNNA has been described.[1]
Analogues
Analogues of IDNNA include DOI, N-methyl-DOI, methyl-DOB (N-methyl-DOB), Beatrice (N-methyl-DOM), N-methyl-DOET, N-methyl-2C-I, and N-methyl-2C-B, among others.[1][2][3]
History
IDNNA was first described in the scientific literature by Alexander Shulgin and colleagues in 1982.[4] Subsequently, it was described in greater detail by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.[1]
Society and culture
Legal status
Canada
IDNNA is a controlled substance in Canada under phenethylamine blanket-ban language.[5]
United Kingdom
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[6]